[go: up one dir, main page]

CL2022003646A1 - Derivados de amidopirimidona - Google Patents

Derivados de amidopirimidona

Info

Publication number
CL2022003646A1
CL2022003646A1 CL2022003646A CL2022003646A CL2022003646A1 CL 2022003646 A1 CL2022003646 A1 CL 2022003646A1 CL 2022003646 A CL2022003646 A CL 2022003646A CL 2022003646 A CL2022003646 A CL 2022003646A CL 2022003646 A1 CL2022003646 A1 CL 2022003646A1
Authority
CL
Chile
Prior art keywords
amidopyrimidone
derivatives
formula
present
compounds
Prior art date
Application number
CL2022003646A
Other languages
English (en)
Inventor
Simon Bell Andrew
Besnard Jérémy
Richard Bradley Anthony
Green Luke
Haap Wolfgang
Kocer Buelent
Kuglstatter Andreas
Lucas Xavier
Mattei Patrizio
Mazunin Dmitry
Ratni Hasane
Riemer Claus
Paul Van Hoorn Willem
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of CL2022003646A1 publication Critical patent/CL2022003646A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/95—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in positions 2 and 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

La presente invención proporciona compuestos de fórmula I o II: en donde X1, X3, R1, R2, R3, R4 y R5 son como se describen en la presente, así como sales farmacéuticamente aceptables de estos. Asimismo, la presente invención se refiere a la elaboración de los compuestos de fórmula I, composiciones farmacéuticas que los comprenden y su uso como medicamentos.
CL2022003646A 2020-06-22 2022-12-19 Derivados de amidopirimidona CL2022003646A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP20181341 2020-06-22

Publications (1)

Publication Number Publication Date
CL2022003646A1 true CL2022003646A1 (es) 2023-08-04

Family

ID=71120055

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2022003646A CL2022003646A1 (es) 2020-06-22 2022-12-19 Derivados de amidopirimidona

Country Status (18)

Country Link
US (2) US20230227449A1 (es)
EP (1) EP4168394A1 (es)
JP (1) JP2023531021A (es)
KR (1) KR20230027042A (es)
CN (1) CN115867541A (es)
AR (1) AR122704A1 (es)
AU (1) AU2021295413A1 (es)
BR (1) BR112022026080A2 (es)
CA (1) CA3181790A1 (es)
CL (1) CL2022003646A1 (es)
CO (1) CO2023000056A2 (es)
CR (1) CR20220638A (es)
IL (1) IL297879A (es)
MX (1) MX2022015886A (es)
PE (1) PE20230685A1 (es)
PH (1) PH12022553420A1 (es)
TW (1) TW202216707A (es)
WO (1) WO2021259815A1 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115215862A (zh) * 2021-04-19 2022-10-21 武汉人福创新药物研发中心有限公司 嘧啶酮化合物及其用途
AU2022373595A1 (en) 2021-10-20 2024-05-02 Insilico Medicine Ip Limited Methionine adenosyltransferase 2a (mat2a) inhibitors and uses thereof
CN114751856A (zh) * 2022-03-27 2022-07-15 江苏壹药新材料有限公司 一种5-碘-6-甲基烟腈的合成方法
KR20250016234A (ko) * 2022-06-27 2025-02-03 씨에스피씨 종콰이 팔마씨우티컬 테크놀로지 (스자좡) 컴퍼니 리미티드 삼환 화합물 및 이의 용도
WO2024217493A1 (en) * 2023-04-19 2024-10-24 Insilico Medicine Ip Limited CRYSTALLINE METHIONINE ADENOSYLTRANSFERASE 2a (MAT2A) INHIBITOR AND USES THEREOF
CN116283800B (zh) * 2023-05-16 2023-07-18 英矽智能科技(上海)有限公司 氧代喹唑啉类化合物及其应用

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AUPO440496A0 (en) * 1996-12-30 1997-01-23 Fujisawa Pharmaceutical Co., Ltd. Quinazoline derivatives
JP2001354567A (ja) * 2000-04-13 2001-12-25 Nippon Zoki Pharmaceut Co Ltd 皮膚炎治療剤
EP1958666A1 (en) 2007-02-13 2008-08-20 Speedel Experimenta AG Heterocyclic-substituted alkanamides as therapeutic compounds
US20100113391A1 (en) * 2007-04-19 2010-05-06 Astellas Pharma Inc. Bicyclic heterocyclic compound
WO2009111547A1 (en) 2008-03-04 2009-09-11 Wyeth 7h-pyrrolo[2,3-h]quinazoline compounds, their use as mtor kinase and pi3 kinase inhibitors, and their synthesis
US20100036123A1 (en) 2008-08-07 2010-02-11 Wyeth Process for the preparation of 2,4-dichloro-7h-pyrrolo[2,3h]quinazoline
EP2398324B1 (en) 2009-02-23 2014-09-03 Merck Sharp & Dohme Corp. PYRAZOLO [4,3-c]CINNOLIN-3-ONE M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS
CN102516339B (zh) * 2010-10-21 2014-03-19 四川大学华西医院 嘧啶并嘧啶化合物及其核苷类似衍生物和制备方法及用途
WO2018132372A1 (en) 2017-01-10 2018-07-19 Sanford Burnham Prebys Medical Discovery Institute Small molecule activators of nicotinamide phosphoribosyltransferase (nampt) and uses thereof
CN113166078B (zh) * 2018-12-10 2024-11-19 伊迪亚生物科学有限公司 2-氧代喹唑啉衍生物作为甲硫氨酸腺苷转移酶2a抑制剂
US20220098203A1 (en) * 2018-12-27 2022-03-31 Les Laboratoires Servier Sas Aza-heterobicyclic inhibitors of mat2a and methods of use for treating cancer
US20220251109A1 (en) * 2019-04-28 2022-08-11 Genfleet Therapeutics (Shanghai) Inc. Oxaazaquinazoline-7(8h)-ketone compound, preparation method therefor and pharmaceutical application thereof
EP4165040A1 (en) * 2020-06-10 2023-04-19 Ideaya Biosciences, Inc. 2-aminoquinazolinone derivatives as methionine adenosyltransferase 2a inhibitors

Also Published As

Publication number Publication date
CR20220638A (es) 2023-01-31
IL297879A (en) 2023-01-01
KR20230027042A (ko) 2023-02-27
TW202216707A (zh) 2022-05-01
BR112022026080A2 (pt) 2023-01-17
JP2023531021A (ja) 2023-07-20
US20230227449A1 (en) 2023-07-20
AR122704A1 (es) 2022-09-28
MX2022015886A (es) 2023-01-24
CO2023000056A2 (es) 2023-03-27
PH12022553420A1 (en) 2024-04-22
PE20230685A1 (es) 2023-04-21
EP4168394A1 (en) 2023-04-26
US20240400556A1 (en) 2024-12-05
CA3181790A1 (en) 2021-12-30
CN115867541A (zh) 2023-03-28
AU2021295413A1 (en) 2022-12-01
WO2021259815A1 (en) 2021-12-30

Similar Documents

Publication Publication Date Title
CL2022003646A1 (es) Derivados de amidopirimidona
UY39296A (es) Azaquinolonas sustituidas inhibidoras de parp y composiciones farmacéuticas que las contienen
UY38076A (es) Derivados de tetrahidroquinazolina útiles como agentes anticáncer
MX2022001789A (es) Derivados de 2-hidroxicicloalcan-1-carbamoilo.
MX2018011831A (es) Antagonistas solubles de receptor de c5aa(c5ar).
CU20220005A7 (es) Inhibidores tricíclicos de kars dependientes de akr1c3
UY31481A1 (es) Nuevos derivados de pirimidina, procesos de preparacion, composiciones farmacéuticas conteniéndolos y aplicaciones
CL2021002165A1 (es) Nuevos derivados de compuestos heterociclicos y uso de los mismos
UY33500A (es) Derivados de acil sulfonamida y sus sales farmacéuticamente aceptables para uso en medicina
CL2023002322A1 (es) Derivados de hidroxiheterocicloalquil-carbamoilo
CL2020001817A1 (es) Moduladores del receptor c5a
UY27851A1 (es) Difenilazetidinonas sustituidas en anillo, procedimiento para su preparacion, medicamentos que comprenden estos compuestos y su uso.
CL2008003639A1 (es) Compuestos derivados de amida; composición farmacéutica que comprende a dicho compuesto; combinación farmacéutica; y uso del compuesto en el tratamiento del vih.
MX2019013639A (es) Derivados de indol n-sustituidos.
CL2023002578A1 (es) Derivados de alfa-d-galatopiranosido triazolil-metil sustituidos
CO2018001700A2 (es) Derivados de n-[1h-bencimidazol-2-il] metil-pirazin-2-il-carboxamida, composiciones y procedimientos de preparación de los mismos
MX389378B (es) Derivados de amino-imidazopiridina novedosos como inhibidores de cinasa de janus y uso farmacéutico de estos.
UY32055A (es) Derivados sustituidos de la 5-Halo-N2-[sustituido](1-metil-1H-imidazol-4-il)pirimidin-2,-diamina y sus sales farmacéuticamente aceptables, procesos de preparación, composiciones y aplicaciones.
UY39181A (es) COMPUESTOS Y COMPOSICIONES PARA INHIBIR LA ACTIVIDAD DE HIF2a Y SUS MÉTODOS DE USO
PE20210550A1 (es) Compuestos de 4-metildihidropirimidinona y su uso farmaceutico
MX2018010177A (es) Compuestos de 6,7-dihidro-5h-pirazolo[5,1-b][1,3]oxazina-2-carboxa mida.
DOP2021000103A (es) Pirazoles como moduladores de hemoglobina
CO2023010155A2 (es) Derivados de pirazolamida
DOP2022000073A (es) Derivados de 2-azaspiro[3,4]octano como agonistas de m4
CL2021003348A1 (es) Derivados de piridin–3–ilo.